Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View

Table 4

Ongoing treatment studies evaluating VEGF MoAbs in cervical cancer patients.

Protocol number	Disease stage	Target therapy	Adjuvant treatment	Study phase	PI
NCT00292955	locally advanced/metastatic	Cetuximab	Cisplatin + radiotherapy	Phase II	Linda R. Duska, M.D
NCT00104910	Stages Ib-IVA	Cetuximab	Cisplatin + radiotherapy + brachitherapy	Phase I	John H. Farley, MD
NCT00997009	Advanced/Recurrent	Cetuximab	Paclitaxel + carboplatin	Phase II	Sandro Pignata, MD
NCT00957411	Stages IB-IIIB	Cetuximab	Cisplatin	Phase II	Susan Scholl, MD
NCT01158248	Stages Ib-III	Panitumumab	Cisplatin + Radiotherapy + brachitherapy	Phase II	Alain Zeimet
NCT01301612	Adenocarcinoma	Nimotuzumab	Cisplatin + Radiotherapy + brachitherapy	Phase II	Sergio Lago